A phase II study of Bevacizumab plus Paclitaxel followed by Eribulin maintenance therapy in patients with HER2-negative metastatic breast cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2017
At a glance
- Drugs Eribulin (Primary) ; Bevacizumab; Paclitaxel
- Indications Breast cancer
- Focus Therapeutic Use
- 05 Apr 2017 Planned number of patients changed from 43 to 53.
- 23 Mar 2016 Planned End Date changed from 31 Dec 2016 to 31 Dec 2020.
- 23 Mar 2016 Status changed from recruiting to active, no longer recruiting.